EICHORCondition: HER-2 Positive Malignant Carcinoma of Breast · HER-2 Protein Overexpression · HER2-positive Metastatic Breast Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | — |
| Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown, New Jersey, United States | — |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | — |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack, New York, United States | — |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | — |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | — |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre, New York, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04692831